Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone

Marina Peball,Florian Krismer,Hans‐Günther Knaus,Atbin Djamshidian,Mario Werkmann,Federico Carbone,Philipp Ellmerer,Beatrice Heim,Kathrin Marini,Dora Valent,Georg Goebel,Hanno Ulmer,Heike Stockner,Gregor K. Wenning,Raphaela Stolz,Kurt Krejcy,Werner Poewe,Klaus Seppi,Collaborators of the Parkinson's Disease Working Group Innsbruck,

DOI: https://doi.org/10.1002/ana.25864

IF: 11.2

2020-08-31

Annals of Neurology

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To assess the efficacy and safety of nabilone, a synthetic tetrahydrocannabinol analogue, as a treatment for non‐motor symptoms (NMS) in Parkinson´s Disease (PD).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>This was a phase II placebo‐controlled, double‐blind, parallel‐group, enriched enrollment randomized withdrawal trial at the Medical University Innsbruck. A random sample of 47 PD patients with stable motor disease and disturbing NMS defined by a score of ≥4 points on the Movement Disorder Society‐Unified PD Rating Scale‐I (MDS‐UPDRS‐I) underwent open‐label nabilone titration (0.25mg once daily‐1mg twice daily, Phase 1). Responders were randomized 1:1 to continue with nabilone or switch to placebo for four weeks (Phase 2). The primary efficacy criterion was the change of the MDS‐UPDRS‐I between randomization and week four. Safety was analyzed in all patients who received at least one nabilone dose.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Between October 2017 and July 2019, 19 patients received either nabilone (median dose=0.75mg) or placebo. At week four, mean change of the MDS‐UPDRS‐I was 2.63 (95%CI 1.53‐3.74, p=0.002, effect size=1.15) in the placebo versus 1.00 (95%CI ‐0.16‐2.16, p=0.280, effect size=0.42) in the nabilone‐group (difference:1.63, 95%CI 0.09‐3.18, p=0.030, effect size=0.66). Seventy‐seven percent of patients had adverse events (AEs) during open‐label titration, most of them were transient. In the double‐blind phase, similar proportions of patients in each group had AEs (42% placebo‐group, 32% nabilone‐group). There were no serious AEs.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Interpretation</h3><p>Our results highlight the potential efficacy of nabilone for PD patients with disturbing NMS, which appears to be driven by positive effects on anxious mood and night‐time sleep problems.</p><p>Trial registry: <a class="linkBehavior" href="http://clinicaltrials.gov">ClinicalTrials.gov</a> (NCT03769896) and EudraCT (2017‐000192‐86) </p><p>This article is protected by copyright. All rights reserved.</p></section>

neurosciences,clinical neurology